• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax

byDayton McMillan
June 6, 2019
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab.

2. Rates of adverse events in the two treatment groups were similar.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Many patients with CLL are elderly and have clinically relevant comorbid health conditions. The BCL2 antiapoptotic protein is overexpressed in CLL, and venetoclax is an oral BCL2 homology domain 3 mimetic compound which aids to induce apoptosis in B-cells. Whether venetoclax can improve treatment efficacy in CLL patients with comorbidities while limiting toxicity is undetermined. This open-label, phase 3 trial showed progression-free survival is significantly increased in patients taking venetoclax as part of their treatment regimen. Adverse outcomes compared to the current standard treatment regimen were similar.

This study supports the use of venetoclax in CLL patients with comorbidities as it optimizes a key survival outcome while toxicity is comparable with the current treatment standard. The study is limited in its strength to detect a difference in overall survival.

Click to read the study, published today in NEJM

Relevant Reading: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia

RELATED REPORTS

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

In-Depth [randomized controlled trial]: This phase 3, open-label, randomized controlled trial enrolled patients in 21 countries. Eligible patients had untreated CD20+ CLL and a Cumulative Illness Rating Scale score of greater than 6. Patients were randomized in a 1:1 fashion to either venetoclax–obinutuzumab (n=216) or chlorambucil–obinutuzumab (n=216) groups. Patients in both groups were treated for 12 cycles lasting 28 days each. Venetoclax dosage was ramped-up over 5 weeks until the full treatment dosage was reached. The primary end point of progression-free survival at 24 months showed a higher rate in the venetoclax group (88.2%; 95% confidence interval [CI], 83.7 to 92.6) compared to the chlorambucil group (64.1%; 95% CI, 57.4 to 70.8). At a medial follow-up of 28.1 months, 30 and 77 primary end point events had been reached in the venetoclax and chlorambucil groups, respectfully (hazard ratio, 0.35; 95% CI, 0.23 to 0.53; P<0.001). An increased progression-free survival in the venetoclax group was seen in patients with a TP53 deletion or mutation. At 3 months after treatment completion, more venetoclax treated patients were negative for minimal disease residue in either the blood or the bone marrow. Patients with any degree of treatment response was also higher in the venetoclax group (84.7% vs. 71.3%, P<0.001), and significantly more patients also experienced complete response in the venetoclax group (49.5% vs. 23.1%, P<0.001). At least one adverse event was reported in greater than 94% of participants in either group. Adverse events leading to treatment discontinuation occurred in approximately 16% of patients in both groups. Tumor lysis syndrome and fatal adverse events also occurred at similar rates between the two groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: BCL2chlorambucilchronic lymphocytic leukemia (CLL)Obinutuzumabvenetoclax
Previous Post

Better supporting the care needs of older adults with disabilities could reduce Medicare spending

Next Post

The VADT-F trial: major cardiovascular events or death are not reduced in diabetics with intensive glucose control therapy

RelatedReports

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia
StudyGraphics

#VisualAbstract: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab treatment does not show added activity in chronic lymphocytic leukaemia

March 24, 2022
#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma
StudyGraphics

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

December 31, 2021
#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation
StudyGraphics

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

November 11, 2021
#VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma
StudyGraphics

#VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma

October 21, 2021
Next Post
Insulin costs rose exponentially, regardless of formulation or patent

The VADT-F trial: major cardiovascular events or death are not reduced in diabetics with intensive glucose control therapy

The MORDOR II trial: mass azithromycin distribution decreases childhood mortality in Niger

The MORDOR II trial: mass azithromycin distribution decreases childhood mortality in Niger

Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine

Quick Take: Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options